[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627435":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":11,"locations":23,"responsibleParty":43,"collaborators":11,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":11,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":25,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":11},"Control","NO_INTERVENTION",null,{"label":13,"type":14,"description":11,"interventionNames":15},"Progesterone","EXPERIMENTAL",[16],"Drug: Progesterone supplementation",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Progesterone supplementation","Patients in the progesterone arm will be randomized to receive progesterone supplementation while the control arm will not receive any additional intervention.",[13],[24],{"facility":5,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"RECRUITING","Charleston","South Carolina","29401","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-79.93275,32.77632,{"lat":35,"lon":34},[38],{"name":39,"role":40,"phone":41,"phoneExt":11,"email":42},"Lauren Yacobucci, MD","CONTACT","7163415115","yacobucc@musc.edu",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Brittany Austin","Assistant Professor-Faculty","100627435","phase-4-progesterone-preeclampsia-100627435",false,"NCT07448597","Progesterone Preeclampsia","Progesterone Supplementation for the Prevention of Preeclampsia","Inclusion Criteria:\n\n* Pregnant individuals receiving prenatal care at participating clinics\n* \\\u003C12 weeks gestation with a viable intrauterine pregnancy\n* Age ≥18 years\n* English-speaking\n\nExclusion Criteria:\n\n* Unable or unwilling to self-administer vaginal progesterone\n* Inability or unwillingness to provide informed consent",true,"FEMALE","18 Years",{"count":58,"type":59},642,"ESTIMATED","INTERVENTIONAL",[62],"PHASE4","This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal morbidity-will be collected via chart review. The study aims to determine whether early progesterone supplementation decreases the risk of preeclampsia.",[65,66],"Preeclampsia","Hypertensive Disorder of Pregnancy",[13],"2026-08-13",{"date":70,"type":71},"2026-08-17","ACTUAL",{"date":68,"type":71},{"date":74,"type":59},"2028-08-01",{"name":5,"class":6},1]